nivolumab
bms
['nivolumab', 'urothelial', 'renal,(-adrenal)', 'check,mate,274', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'bladder']
 checkmate 274 trial update at median follow-up 36.1 months. median dfs 22.0 months nivolumab vs 10.9 months w/placebo, [hr] 0.71. patients w/ pd-l1 1%, nivolumab median dfs 52.6 mo vs. 8.4 mo w/placebo (hr 0.52) #gu23 
🎗Oncologist|🧬Cancer Researcher|President Ky @ASCO|MedSchool Professor @UofL|Faculty @ASCO @NCCN @OncoAlert|Advisor @MedScape @Onclive @Doximity|#MedTwitter